Exelixis price target raised to $46 from $43 at RBC Capital
RBC Capital raised the firm's price target on Exelixis to $46 from $43 and keeps a Sector Perform rating on the shares as part of a broader research note previewing Q2 earnings in Biotech. The biotech sector has picked up considerable momentum, with a near-unprecedented two-week move in June relative to the S&P - drive